SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is capturing attention through persistent community engagement, frequent social media trending, and ongoing poker events that keep the ecosystem active. The community is focused on long-term project viability, often utilizing humorous wordplay and cross-promotion with other projects to maintain momentum.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is capturing significant community attention as a high-momentum memecoin drawing comparisons to other viral market breakouts. Investors are actively debating the sustainability of its rapid price appreciation, with some highlighting its potential as a leader in the latest community-takeover trend while others remain skeptical of the inherent volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto is capturing significant attention as the community rallies around the restoration of iconic internet meme culture through its dedicated platforms. Supporters emphasize long-term conviction and consistent daily engagement, positioning the project as an essential, history-backed movement within the broader meme coin landscape.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility following a rapid price surge and subsequent sharp collapse, sparking heated community debate over allegations of a coordinated pump-and-dump scheme. Investors are currently divided between those warning of a potential rug pull and participants attempting to trade the extreme price swings as the project denies involvement in the manipulation.

LayerZero

LayerZero ($ZRO) is trending as the community highlights its role in cross-chain interoperability, specifically through its integration with the meme coin $CAW. Investors are actively discussing the potential of this partnership and the broader utility of LayerZero's bridging technology in a multi-chain ecosystem.

Got that dog in you? - Fueled by a mantra of tokenized self-belief, doginme is representative of the community's collective efforts to embrace and embolden that dog in them. doginme stands for knowing yourself and having that unshakable drive to keep pushing forward. doginme was originally launched in February 2024 when the Farcaster founder was asked if he owned a dog, to which he replied affirmatively: "no but I got that dog in me"

doginme

DOGINME continues to capture investor interest as community members lean into the "dog in me" narrative, emphasizing resilience and self-belief as key cultural drivers for the token. Discussions are currently dominated by momentum builds and potential breakout opportunities as the pack rallies around the asset's low market cap and viral potential within the Base ecosystem.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is testing critical resistance levels near $76,000 to $80,000, with the community actively debating whether this represents a textbook rejection or a precursor to a parabolic breakout. Traders are focused on technical signals, including moving average tests and flag structures, as market sentiment balances between short-term caution regarding geopolitical volatility and long-term bullishness fueled by institutional adoption.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate the impact of leadership changes and the company's massive cash pile, with community sentiment deeply divided between critics highlighting recent performance struggles versus supporters betting on an inevitable breakout. Tensions remain high as shareholders discuss the stock's significant underperformance against the S&P 500, focusing heavily on whether new leadership can effectively deploy capital and overcome the "Buffett premium" compression.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is capturing attention as community members debate its potential against other established meme assets, fueled by its deep roots in internet culture and its active presence across various social platforms. Investors are closely watching its market movements while frequently comparing its long-term viability and memetic power to other iconic tokens.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing attention as market participants weigh its long-term DeFi utility and strong institutional positioning against recent volatility and sector-wide concerns about bad debt. While some traders are expressing caution regarding broader market pressures, many are actively discussing the protocol's recovery potential and its role as a foundational asset in the current DeFi landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.&nbsp;</li><li>The executive order directs Trump’s administration to initiate the steps needed for the classification shift.</li></ul>Shares of Tilray Brands, Aurora Cannabis and Trulieve Cannabis pulled back on Thursday after an early rally sparked by U.S. President Donald Trump’s executive order to ease federal restrictions on marijuana lost momentum, as investors pared gains following the initial reaction to the policy move.Shares of TLRY and ACB fell 5% and 3% respectively at the time of writing while TCNNF dropped 17%.&nbsp;<h2 class="st-heading-2">Trump Pushes Medical Marijuana</h2>President Donald Trump on Thursday signed an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.”Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.“We have people begging for me to do this, people that are in great pain for decades,” Trump said while referring to patients suffering from extreme pain and incurable diseases including cancer. The executive order directs Trump’s administration to initiate the steps needed for the classification shift.“Schedule III status will allow research studies to incorporate real-world evidence and models that can assess the health outcomes of medical marijuana and legal CBD products while focusing on long-term health effects in vulnerable populations like adolescents and young adults,” the White House said in a statement.State regulations on cannabis are currently complex. While a few U.S. states currently permit the recreational use of cannabis, some allow it for medical purposes.<h2 class="st-heading-2">How Did Trump Decide?</h2>According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-18/trump-signs-order-to-reclassify-marijuana-in-industry-win">report</a> from Bloomberg, Trump came to the decision following discussions with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz as well as cannabis-industry leaders including Trulieve Cannabis Corp CEO Kim Rivers. As per the report, the Centers for Medicare &amp; Medicaid Services is also expected to complete a plan to test making some Medicare patients eligible for therapies derived from cannabinoids.Jazz Pharmaceuticals’ Epidiolex is currently the only drug approved by the U.S. Food and Drug Administration composed of CBD, a psychoactive compound found in cannabis.<h2 class="st-heading-2">Tilray Plans Expansion With Trump’s Push</h2>Tilray, a producer and distributor of medical and adult-use cannabis, subsequently confirmed plans to advance its U.S. medical cannabis operations with the formation of a unit called Tilray Medical USA, Inc. The unit aims to introduce medical-grade cannabis products in targeted therapeutic formats, the company said.“This action [executive order] aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity,” Tilray CEO Irwin D. Simon said.<h2 class="st-heading-2">Other Cannabis Firms Respond To Policy Change</h2>Cresco Labs applauded the executive order terming it a “cultural turning point” and a “historic shift.” Trulieve too applauded the decision while <a href="https://stocktwits.com/symbol/SMG">Scotts Miracle-Gro</a> expressed support highlighting that 39 states already legalize cannabis in some form. Scotts expects to combine its Hawthorne Gardening company subsidiary, which provides nutrients, lighting and other supplies to legal cannabis growing operations, with a cannabis company in 2026.<a href="https://stocktwits.com/symbol/HITI">High Tide</a> said that it is exploring structures that would allow it to expand its Canna Cabana retail brand into the U.S. through licensing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> and <a href="https://stocktwits.com/symbol/CGC">CGC</a> trended in the ‘extremely bullish’ territory at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF</a> (MSOS), which tracks American operators, followed suit.TLRY and CGC shares are down 8% and 39% this year, respectively.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-eyes-ex-tesla-employee-sterling-anderson-as-potential-successor-to-ceo-mary-barra-report/cLegDrmRErL">General Motors Eyes Ex-Tesla Employee Sterling Anderson As Potential Successor To CEO Mary Barra: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Tilray, Aurora Cannabis, Trulieve Pull Back After Trump Marijuana Order Rally Runs Out Of Steam

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research.

Equity

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide, but is instead aimed at improving medical marijuana and cannabidiol research.


Trump Orders Federal Action to Accelerate Cannabis Research Access

President Trump directed federal agencies Thursday to complete the marijuana rescheduling process initiated under the previous administration, focusing the executive action on expanding medical research opportunities for cannabis and CBD compounds.The executive order instructs the attorney general to finalize the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act, a shift that administration officials characterized as removing bureaucratic obstacles to scientific study rather than addressing recreational use or criminal penalties.In a press ...

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

Stocks of cannabis sellers Tilray Brands Inc. and Canopy Growth Corp.&nbsp;fell 5% and 1.3%, respectively, in the early premarket session on Tuesday.Weed stocks&nbsp;seem to be losing momentum from the previous day, when the sector rallied following President Donald Trump's post highlighting the potential benefits of using cannabidiol in senior healthcare.Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115283887618990920">video post</a> on Truth Social on Sunday.Major companies&nbsp;<a href="https://stocktwits.com/symbol/CURLF">Curaleaf Holdings</a>,&nbsp;<a href="https://stocktwits.com/symbol/TCNNF">Trulieve Cannabis</a>, and&nbsp;<a href="https://stocktwits.com/symbol/GLASF">Glass House Brands</a> rose 37% to 21% on Monday. They have over-the-counter (OTC) shares listed in the U.S., which do not trade pre- and after-market.<a href="https://stocktwits.com/symbol/TLRY">Tilray shares</a> gained 60% hitting a 52-week high, while&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy stock</a> ended 17% higher.On Stocktwits, the retail sentiment was 'extremely bullish' for Tilray, 'bullish' for Curaleaf, Canopy, and Trulieve, and 'bearish' for Glass House, as of early Tuesday.A bullish user projected strong gains in the stocks should a formal announcement regarding the CBD be made.<stembedurl>https://stocktwits.com/angelfromsky/message/630185575</stembedurl>Trump said last month that his administration was weighing a reclassification of marijuana. The potential move would classify marijuana as less dangerous under federal law and could lead to easing criminal penalties tied to its use.Meanwhile, regulations around the commercial use of hemp and CBD were significantly eased through the Agriculture Improvement Act, enacted during Trump's first term. As of now, marijuana remains listed as a Schedule I substance under the Controlled Substances Act, meaning it has a high potential for abuse and no current accepted medical use.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dozens of varieties of marijuana samples are on display at a dispensary in New York. (Photo by John Paraskevas/Newsday RM via Getty Images)

Tilray, Canopy Growth: Cannabis Stocks Lose High Premarket After Surge Triggered By Trump's Post

Major weed stocks rallied the previous day after President Donald Trump's post, which highlighted the potential benefits of using cannabidiol in senior healthcare.

President Donald Trump confirmed on Monday that he is looking at reclassifying marijuana and may announce his final decision in the next few weeks. "We're looking at reclassification, and we'll make a determination over the next few weeks," Trump told reporters during a press conference about cracking down on crime in Washington, D.C.His comments come after The Wall Street Journal (WSJ)&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c">reported</a> last week that Trump may be interested in changing the drug’s classification. Marijuana-linked stocks like Aurora Cannabis (ACB), Canopy Growth (CGC), Tilray Brands (TLRY), Cronos Group (CRON), and Trulieve Cannabis (TCNNF) were already rallying in pre-market trade on the report.&nbsp;They continued to rally after Trump’s confirmation, with&nbsp;<a href="http://stocktwits.com/symbol/CGC">Canopy Growth’s</a> stock surging nearly 30% in midday trade.&nbsp;<a href="http://stocktwits.com/symbol/TLRY">Tilray’s stock</a> jumped 22%, followed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://tcnnf">Trulieve’s stock</a> gaining more than 18%. Aurora Cannabis’s stock climbed 12.5% on Monday.On Stocktwits, retail sentiment around Canopy Growth moved higher within ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter. Meanwhile, retail sentiment around Tilray Brands improved to ‘bullish’ from ‘bearish’ a day ago, and retail sentiment around Trulieve was moved higher within ‘extremely bullish’ territory.“Some people like it. Some people hate it. Some people hate the whole concept of marijuana, because if it’s bad for the children, it’s bad for people older than children,” the President said, noting that medical marijuana, specifically, may hold benefits.&nbsp;“I’ve heard great things to do with medical, and I’ve heard bad things having to do with just about everything else but medical,” he said.Reclassification of marijuana from a Schedule I drug to a Schedule III drug would ease restrictions, allow tax breaks, and expand medical research.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-declares-liberation-day-in-dc-pushes-takeover-of-city-police/chrHGOoRdee">Trump Declares ‘Liberation Day’ in DC, Pushes Takeover Of City Police</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions during a press conference in the James S. Brady Press Briefing Room of the White House August 11, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Trump Confirms Marijuana Reclassification Decision To Be Made In ‘Next Few Weeks’ 

The President noted that there’s a difference of opinion on the benefits of marijuana, but added that he’s heard “great things” with respect to medical marijuana, specifically.

Retail sentiment picked up Sunday for Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON) and Trulieve Cannabis (TCNNF) after reports that U.S. President Donald Trump may reclassify marijuana as a less dangerous drug.&nbsp;The Wall Street Journal&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/politics/policy/trump-marijuana-federal-drug-classification-01a73b8c">said</a> that at a $1 million-a-plate fundraiser at his New Jersey golf club earlier this month, Trump told guests he was interested in the change, signaling an effort the Biden administration had started but never completed.Reclassification to Schedule III would ease restrictions, allow tax breaks, and expand medical research. Trulieve CEO Kim Rivers reportedly urged Trump to pursue the shift and expand research. Trump flagged the idea to staff. Other guests included Pfizer’s CEO, cryptocurrency executives, and political advisers.Cannabis companies have contributed millions to Trump’s political groups, hired lobbyists close to him, and backed American Rights and Reform PAC, which gave $1 million to Trump’s PAC and commissioned polling from Trump pollster Tony Fabrizio showing Republican and independent voter support.The PAC also paid $300,000 to Trump adviser Alex Bruesewitz for social media and advertising work.Bruesewitz said, “This is not calling for decriminalization or legalization but simply knocking it down a few notches on the criminal scale.”Trump said last year he would vote for legalization in Florida after meeting with Trulieve and lobbyist Brian Ballard. Senior officials said he does not personally support marijuana but is interested in “80-20 cultural issues” with broad backing and has referenced friends who used medical marijuana.Opposition groups include Smart Approaches to Marijuana, which has run ads on Fox programs, and the Community Anti-Drug Coalitions of America, which urged members to contact the White House.White House spokeswoman Abigail Jackson said, “All policy and legal requirements and implications are being considered. The only interest guiding the president’s policy decisions is what is in the best interest of the American people.”On Stocktwits, retail sentiment was “extremely bullish” with “high” message volume for ACB, CGC, and TCNNF, while CRON was “bullish” with “high” message volume.One user noted that cannabis company stocks jumped between 30% and 40% after multiple reports in April 2024 that marijuana would be reclassified to a less dangerous drug schedule.<stembedurl>https://stocktwits.com/Icarus81/message/624511957</stembedurl>Another user pointed out that the last time there was similar regulatory talk, ACB rose sharply to more than $8 a share, and said it should be “an interesting week to say the least.”<stembedurl>https://stocktwits.com/LionsFan/message/624533180</stembedurl>So far this year, ACB is up 5.4%, CGC is down 54.4%, CRON is up 13.9% and TCNNF is up 10.5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

So far this year, ACB is up 5.4%, CGC is down 54.4%, CRON is up 13.9% and TCNNF is up 10.5%. (Photo credit: Getty Images)

Retail Bulls Pile Into Cannabis Stocks On Reports Trump May Reclassify Marijuana; Traders Eye Aurora Rally

Cannabis firms have spent millions lobbying Trump to shift marijuana to Schedule III, easing restrictions and enabling tax breaks.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

TCNNF
Trulieve Cannabis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TCNNF News

TCNNFTrulieve Cannabis